newsmetry
rusign inget started
macro

Novo Nordisk: Cagrisema cut weight 20.7–21% over 68 weeks in REDEFINE 9

Novo Nordisk reported that Cagrisema helped trial participants lose about 21% of body weight over 68 weeks, versus 2% on placebo, in REDEFINE 9.

published on Newsmetry
original source published

the same feed is available to bots and dashboards through the api. connect the api →

Newsmetry newsroom

what happened

Novo Nordisk reported results from the REDEFINE 9 trial, according to Reuters. At the 1.7 mg/1.7 mg dose, average weight loss reached 20.7% over 68 weeks, and at the 1.0 mg/1.0 mg dose it reached 21.0%. The placebo group lost 2.0%.

Waist circumference fell by 17.2–17.5 cm in both Cagrisema groups, compared with 3.6 cm on placebo. A significantly larger share of adults reached weight reductions of at least 5%, 10%, 15% and 20%. The company said the safety profile at both doses was consistent with earlier Cagrisema trials.

why it matters

For markets, the data confirm the combination's effect against placebo and keep the safety picture in line with prior studies. This supports investor interest in the company's weight-loss pipeline, which remains one of Novo Nordisk's key growth drivers. The longer-term outlook will depend on further data and regulatory decisions.

market impact

Novo Nordisk shares: strong drug data supports investor interest in the pipeline

  • Novo Nordisk shares pressure up — strong trial results strengthen expectations for the drug

tags

StockDenmark

instruments

Novo NordiskNOVO-B.CONovo Nordisk ADROzempic-related pipeline

sources

  1. Novo Nordisk Cagrisema 1.7 Mg/1.7 Mg Achieved 20.7%, 1.0 Mg/1.0 Mg Achieved 21.0% Average Weight Loss At 68 Weeks Versus 2.0% With Placebo In Redefine 9 Trial — Reuters, 14 November 2026 at 17:00 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗

related stories